2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005
News and Resources
2009 Releases
12/17/2009 - Opexa Therapeutics, Inc. Announces Closing of $5.1 Million Registered Direct Offering
12/10/2021 - Opexa Therapeutics, Inc. Announces $5.1 Million Securities Offering
11/05/2022 - Opexa to Present at the Merriman Curhan Ford 6th Annual Investor Summit 2009
11/04/2022 - Opexa Therapeutics Reports Third Quarter 2009 Financial Results and Corporate Update
09/23/2009 - Opexa Triggers Milestone Payment Under Recently Announced Stem Cell Agreement
09/08/2022 - Opexa Reports Additional Favorable Data with Tovaxin for Multiple Sclerosis
08/13/2009 - Opexa Therapeutics Reports Second Quarter 2009 Financial Results and Corporate Update
08/10/2021 - Opexa Regains NASDAQ Compliance Following Stem Cell Agreement
08/07/2022 - Opexa Announces Stem Cell Agreement with Leading Global Pharmaceutical Company
06/09/2022 - Opexa Therapeutics Receives Favorable NASDAQ Determination
04/27/2009 - Opexa to Present Tovaxin Data at the American Academy of Neurology 2009 Annual Meeting
04/24/2009 - Opexa Publication of Tovaxin Clinical Data in Journal of Clinical Immunology
04/16/2009 - Opexa Therapeutics Reports Year End 2008 Financial Results
04/16/2009 - Opexa Therapeutics Closes First Tranche of Additional Financing
04/06/2022 - Opexa Therapeutics to Present at the Cambria Capital Investor Meeting
03/17/2009 - Opexa's Stem Cell Therapy for Diabetes Shows Progress
03/05/2022 - Opexa Provides Key Quality of Life Data on Tovaxin for Multiple Sclerosis
01/20/2009 - Opexa Provides Update on Various Corporate Developments